Roivant Sciences (ROIV) Research & Development (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of Research & Development data on file, last reported at $482.9 million in Q4 2025.

• Quarterly Research & Development rose 19.17% year-over-year to $482.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (up 20.42% YoY) and the FY2026 annual result came in at $681.8 million, up 23.87% from the prior year.
• Research & Development improved to $482.9 million in Q4 2025, from $164.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $482.9 million in Q4 2025 to a low of $78.5 million in Q2 2021.
• A 5-year average of $217.4 million and a median of $143.1 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development surged 73.0% — and 2023, when it decreased 15.51%.
• Tracing ROIV's Research & Development over 5 years: stood at $348.0 million in 2021, then climbed by 13.05% to $393.4 million in 2022, then fell by 15.51% to $332.4 million in 2023, then climbed by 21.91% to $405.2 million in 2024, then rose by 19.17% to $482.9 million in 2025.
• The last three Research & Development figures came in at $482.9 million (Q4 2025), $164.6 million (Q3 2025), and $152.9 million (Q2 2025), per Business Quant data.